ClinicalTrials.gg
Active, not recruitingNCT06667687Updated Sep 29, 2026

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

A Phase 1 interventional study of ABBV-291 in Non-Hodgkin's Lymphoma, sponsored by AbbVie. Active, not recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Updated Sep 29, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Lymphoma, Non-Hodgkin by AbbVie — 1 open to participants now, 5 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · AbbVie.

Enrollment
23rd of 31
21 · median 60
Started
2025
the only one that year
Phase 1
19 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Lymphoma, Non-Hodgkin by AbbVie, this one is the 23rd largest by enrollment, is the only one that started in 2025, is one of 19 in phase 1, and was the 31st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 31 studies in Lymphoma, Non-Hodgkin by AbbVie is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Lymphoma, Non-Hodgkin by AbbVie, or all of them as a file.
02

Study summary

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed.

ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide

In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

03

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • Non-Hodgkin's Lymphomas
  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Waldenstroms Macrogloulinemia
  • Germinal Center B-cell
  • Activated B-Cell
  • NHL
  • DLBCL
  • MCL
  • FL
  • MZL
  • WM
  • GCB
  • ABC
  • Cancer
  • ABBV-291
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and requiring treatment:

    • Mantle cell lymphoma (MCL);
    • Marginal zone lymphoma (MZL);
    • Waldenstrom macroglobulinemia (WM);
    • Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], Epstein-Barr virus-positive (EBV+) DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, human herpesvirus 8-positive [HHV8+] DLBCL [not otherwise specified], B cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements], DLBCL arising from follicular lymphoma [FL] [transformed FL]);
    • FL Grades 1 to 3B;
  • For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:

    • Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], EBV+ DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, HHV8+ DLBCL [not otherwise specified], B-cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC and BCL2 and/or BCL6 rearrangements], DLBCL arising from FL [transformed FL]);
    • Part 2b only: FL Grades 1 to 3B;
    • Part 2c only: Mantle cell lymphoma;
  • For all participants (Parts 1 and 2):

    • Must be considered to, or intolerant of, at least 2 or more known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or stem cell transplantation [ASCT]).
    • Indolent non-Hodkin's lymphoma (NHL) participants must meet relevant disease specific requirements for treatment (e.g., National Comprehensive Cancer Network [NCCN], Groupe d'Etude des Lymphomes Folliculaires [GELF]).
    • History of allogeneic stem cell transplantation must be stable off of for at least 3 months.
    • For participants enrolled in backfill cohorts or at dose levels previously cleared, subjects must provide consent to an on-treatment fresh tumor from the same tumor lesion as the baseline tumor tissue. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.
    • Previously treated with a CD79b-targeting therapy (e.g., CD79b monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD79b-targeting therapy must be collected. Tumor biopsy requirements may be modified by Sponsor during the study. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

      • CD79b expression status will be assessed in all participants.
  • Have an (ECOG) Performance Status of 0 or 1.
  • Laboratory values meeting the criteria in the protocol within the screening period prior to the first dose of study drug (if multiple samples are drawn within the screening period, the sample/result immediately prior to Cycle 1 Day 1 is applicable).
  • Availability of representative baseline tumor tissue (most recent archived tumor tissue or fresh biopsy collected during screening phase) suitable for immunohistochemistry (IHC) testing. This requirement may be waived at the discretion of the CRO Medical Monitor if collecting a biopsy at screening would place the participant at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a participant's ability to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic , or any evidence of active ILD or pneumonitis.
  • Treatment with any of the following:

    • Anticancer therapy including chemotherapy, radiotherapy, small molecule, , and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment;
    • CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment.
    • Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Escalation: Non-Hodgkin Lymphoma (NHL) ABBV-291

    Participants with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), except chronic lymphocytic leukemia (CLL), will receive escalating doses of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

  • Experimental
    Expansion: Diffuse Large B-Cell Lymphoma (DLBCL) ABBV-291

    Participants with R/R DLBCL will receive the recommended Phase 1 expansion dose (RP1ED) of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

  • Experimental
    Expansion: Follicular Lymphoma (FL) ABBV-291

    Participants with R/R FL will receive the RP1ED of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

  • Experimental
    Optimization: Mantle Cell Lymphoma (MCL) ABBV-291 Dose A

    Participants with R/R MCL will receive the dose A of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

  • Experimental
    Optimization: MCL ABBV-291 Dose B

    Participants with R/R MCL will receive the dose B of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

  • Experimental
    Optimization: MCL ABBV-291 Dose C

    Participants with R/R MCL will receive the dose C of ABBV-291, as part of the 74 month study duration.

    Drug: ABBV-291

Interventions

  • DrugABBV-291

    Intravenous Infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AE)s

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 74 Months

  2. Percentage of Participants with Dose Limiting Toxicities (DLT)s

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to 74 Months

  3. Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology)

    Percentage of participants with clinically significant laboratory values (chemistry, and hematology).

    Time frame: Up to 74 Months

  4. Percentage of Participants with Clinically Significant Vital Sign Measurements

    Vital sign are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

    Time frame: Up to 74 Months

  5. Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings

    Percentage of participants with clinically significant ECG findings.

    Time frame: Up to 74 Months

  6. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed best overall response (BOR) of partial response (PR) or better per disease-specific response criteria (e.g., Lugano classification).

    Time frame: Up to 74 Months

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by Investigator

    DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to disease-specific response criteria to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to 74 Months

  2. Progression-Free Survival (PFS) as Assessed by Investigator

    PFS is defined as time from first study treatment to a documented disease progression according to disease-specific response criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to 74 Months

  3. Time to response (TTR)

    TTR is defined as time from first study treatment to the initial response of PR (or better) per investigator review according to disease-specific response criteria.

    Time frame: Up to 74 Months

  4. Area Under the Curve (AUC) of ABBV-291

    AUC is defined as the area under the plasma/serum concentration-time curve of ABBV-291.

    Time frame: Up to 12 Months

  5. Maximum Observed Plasma/Serum Concentration (Cmax) of ABBV-291

    Cmax is defined as maximum observed plasma/serum concentration of ABBV-291.

    Time frame: Up to 12 Months

  6. Time to Cmax (Tmax) of ABBV-291

    Tmax is defined as time to Cmax of ABBV-291.

    Time frame: Up to 12 Months

  7. Half-Life (t1/2) of ABBV-291

    t1/2 is defined as the half-life of ABBV-291.

    Time frame: Up to 12 Months

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 71. This study's planned 24 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Apr 2027 → Jan 2027 and completion Apr 2027 → Nov 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Oct 31, 2024
StartActual
Jan 16, 2025
Primary completionEst.
Jan 2027was Apr 2027
CompletionEst.
Nov 2031was Apr 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 267470 · Koto-ku, Japan
Show 1 removed
  • The Cancer Institute Hospital Of JFCR /ID# 267470 · Koto-ku, Japan
Sep 29, 2026
Primary completion
Apr 2027→Jan 2027
Sep 29, 2026
Study completion
Apr 2027→Nov 2031
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added, 1 site removed
    Show site
    • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 267470 · Koto-ku, Japan
    Show 1 removed
    • The Cancer Institute Hospital Of JFCR /ID# 267470 · Koto-ku, Japan
    Primary completion Apr 2027→Jan 2027
    Study completion Apr 2027→Nov 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06667687
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 31, 2024
Start date
Jan 16, 2025
Primary completion
Jan 2027 (estimated)
Completion
Nov 2031 (estimated)
Last update
Sep 29, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion